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Abstract 1 
Terbutaline is a prohibited drug except for athletes with a 2 
therapeutic use exemption certificate; terbutaline’s effects on 3 
endurance performance are relatively unknown.  4 
Purpose: To investigate the effects of two therapeutic (2mg; 4mg) 5 
inhaled doses of terbutaline on 3km running time-trial 6 
performance.  7 
Methods: Eight males (24.3±2.4yrs; 77.6±8kg; 179.5±4.3cm) 8 
and eight females (22.4±3yrs; 58.6±6kg; 163±9.2cm) free from 9 
respiratory disease and illness provided written informed 10 
consent. Participants completed 3 km running time-trials on a 11 
non-motorised treadmill on three separate occasions following 12 
placebo, 2 mg or 4 mg inhaled terbutaline, in a single-blind, 13 
repeated-measures design. Urine samples (15mins post-exercise) 14 
were analysed for terbutaline concentration. Data were analysed 15 
using one-way repeated measures ANOVA, significance was set 16 
at p<0.05 for all analyses. 17 
Results: No differences were observed for completion times 18 
(1103±201; 1106±195; 1098±165s; P=0.913) for the placebo 19 
trial, the 2mg inhaled trial and the 4mg inhaled trial, respectively. 20 
Lactate values were higher (P=0.02) following 4mg terbutaline 21 
(10.7±2.3mmol·L-1) vs. placebo (8.9±1.8mmol·L-1).  FEV1 22 
values were greater following inhalation of 2mg (5.08±0.2; 23 
P=0.01) and 4mg terbutaline (5.07±0.2; P=0.02) compared to 24 
placebo (4.83±0.5L) post-inhalation. Urinary terbutaline 25 
concentrations were mean (306±288ng·mL-1; 435±410ng·mL-1; 26 
P=0.2) and peak (956ng·mL-1; 1244ng·mL-1) following 2mg and 27 
4mg inhaled terbutaline, respectively. No differences were 28 
observed between the male and female participants.  29 
Conclusions: Therapeutic dosing of terbutaline does not lead to 30 
an improvement in 3 km running performance despite 31 
significantly increased FEV1. Our findings suggest that athletes 32 
using inhaled terbutaline at high therapeutic doses to treat 33 
asthma will not gain an ergogenic advantage during 3 km 34 
running performance. 35 
 36 
Introduction 37 
Short-acting β2-agonists are used therapeutically by athletes with 38 
asthma related conditions to prevent and/or reverse the 39 
bronchoconstriction of the airways, leading to restoration of 40 
airway function.1–5 The majority of athletes treat symptoms of 41 
exercise-induced bronchoconstriction (EIB) through the use of 42 
salbutamol, making it the most commonly used inhaled β2-43 
agonist in these individuals.4 However other β2-agonists, such as 44 
terbutaline, are available which is a suitable alternative to 45 
salbutamol, should an athlete not respond appropriately to 46 
salbutamol treatment.6–10 Athletes that are subject to World Anti-47 
Doping Agency (WADA) regulations, who require alternative 48 
β2-agonist therapy can apply for a therapeutic use exemption 49 
certificate (TUE) in order to use inhaled terbutaline.11 50 
The prohibited status of terbutaline is due, in part, to the inability 51 
to distinguish between therapeutic inhaled and therapeutic oral 52 
doses (with all oral β2-agonists being banned under the WADA 53 
code), given that an oral dose far exceeds the inhaled dose in 54 
terms of the systemic bioavailability when given 55 
therapeutically.12,13 In some athletes the need for the use of 56 
terbutaline is justified, however there are currently no measures 57 
in place to prevent an athlete with a legitimate TUE for 58 
terbutaline from using the medication at a supratherapeutic dose 59 
with impunity.13  60 
The current WADA guidelines monitor the use of the inhaled 61 
short-acting β2-agonists, salbutamol and formoterol via a urinary 62 
threshold limit, above which will present an adverse analytical 63 
finding (AAF).11 For salbutamol this limit is 1000 ng·mL-1 with 64 
a decision limit of 1200 ng·mL-1 and for formoterol this limit is 65 
40 ng·mL-1 with a decision limit of 50 ng·mL-1, with any levels 66 
over this presenting an AAF. The current guidelines for use 67 
indicate that no more than 1600 µg salbutamol can be inhaled in 68 
a 24 hour period and within this no more than 800 µg can be 69 
inhaled in a 12 hour period, with the equivalent for formoterol 70 
being 54 µg  over a 24 hour period.11 If a threshold for terbutaline 71 
could be determined, this would enable it to be monitored in 72 
much the same way as both salbutamol and formoterol, 73 
preventing an athlete with a TUE for terbutaline from potentially 74 
using the medication at a supratherapeutic dose. Recently 75 
Jacobson et al.,13 presented the case for establishment of dosing 76 
thresholds for terbutaline, these dosing thresholds are extremely 77 
important given recent evidence of ergogenic effects of 78 
supratherapeutic dosages of inhaled terbutaline on sprint and 79 
power performance, muscle strength and muscle hypertrophy, as 80 
well as inducing muscle phenotype alterations.8,9,14,15  81 
The establishment of a urinary threshold for terbutaline has 82 
proven to be difficult to attain, recently Dyreborg et al.,16 83 
examined high-dose (4 mg) inhaled versus oral (10 mg) 84 
terbutaline, finding that the bioavailability and pharmacokinetics 85 
vary distinctly between routes of administration. Peak urinary 86 
concentration of 4 mg inhaled terbutaline occurred 2 hours post-87 
inhalation and peak urinary concentration of 10 mg oral 88 
terbutaline occurred 6 hours post-ingestion, interestingly there 89 
was also no significant difference between urinary levels of 90 
inhaled vs oral terbutaline at the 6 hour stage. Similar work was 91 
previously performed by Elers et al.,12 in which inhaled (2 mg) 92 
and oral (10 mg) terbutaline were examined, the study found that 93 
although there was a significant difference between urine 94 
concentrations dependent upon route of administration, no 95 
threshold was able to be established due to high variability 96 
between individuals. It is therefore important to assess urinary 97 
levels of terbutaline for doping control purposes. 98 
Evidence exists that the use of terbutaline at a supratherapeutic 99 
dose has the potential to be ergogenic.17,18 These purported 100 
effects are due to the fact that short-acting β2-agonists (a class of 101 
sympathomimetic amines) are able to activate the β2 adrenergic 102 
receptors within the body, which are mainly present on bronchial 103 
smooth muscle.19–21 Activation of the β2 adrenergic receptors 104 
reverses the constriction of bronchial smooth muscle during 105 
bronchoconstriction. These same β2 receptors are also present on 106 
cardiac smooth muscle and skeletal muscle.21,22 Adrenergic 107 
activation of skeletal muscle has the potential to improve 108 
musculoskeletal function and thus has the potential to be 109 
ergogenic during exercise performance.23 Recent investigations 110 
suggest an acute supratherapeutic inhaled dose (15 mg) of 111 
terbutaline may have ergogenic action in sprint cycling 112 
performance.8,9,14,18 This 15 mg dose is approximately eight 113 
times the recommended therapeutic dose for inhaled terbutaline 114 
and in athletes with a TUE this would not be permitted according 115 
to the WADA code,11 however current regulations would not be 116 
able to accurately detect this misuse of terbutaline, due to a lack 117 
of urinary thresholds with which to monitor terbutaline use. 118 
Given the ergogenic potential of supratherapeutic inhaled 119 
terbutaline, it remains to be determined whether athletes using 120 
terbutaline therapeutically to treat asthma symptoms could also 121 
experience an ergogenic effect, traditionally the therapeutic dose 122 
of inhaled terbutaline is between 1-2 mg, however studies have 123 
shown therapeutic use as high as 4 mg.10,16  124 
The aim of the present study was to examine the potential 125 
ergogenic action of 2 mg and 4 mg inhaled terbutaline on 126 
exercise performance during a 3 km running time-trial and to 127 
measure urinary thresholds of terbutaline post-exercise 128 
performance. 129 
 130 
Methods 131 
Following ethical approval from the Liverpool John Moores 132 
University research ethics committee (Ethics No. P11SPS044), 133 
eight males (age: 24.3 ± 2.4 years; weight: 77.6 ± 8 kg; height: 134 
179.5 ± 4.3 cm) and eight females (age: 22.4 ± 3 years; weight: 135 
58.6 ± 6 kg; height: 163 ± 9.2 cm) volunteered to participate in 136 
the study, providing their written informed consent. All 137 
participants were in good health, non-smokers and took part in 138 
sport and exercise activities for at least 3 hours per week. No 139 
participant had previously been diagnosed with asthma and/or 140 
EIB, all participants were free from chest infection for at least 141 
two weeks prior to testing. Participants presented with a negative 142 
eucapnic voluntary hyperpnoea (EVH) challenge.24,25 No 143 
participants competed at a level where they were subject to 144 
regular anti-doping tests. Participants were informed about the 145 
nature and the risks of the experimental procedures before 146 
providing written informed consent.  147 
 148 
3 km Time-Trial 149 
The 3 km time-trials were conducted on a non-motorised curved 150 
treadmill (Woodway Curve, Woodway, USA). Participants were 151 
familiarised to running on a non-motorised treadmill prior to 152 
initiating their recorded 3 km time-trials.  Familiarisation runs 153 
took place on at least two occasions and participants progressed 154 
to the recorded 3 km time-trials only once they felt comfortable 155 
pacing themselves on the non-motorised curved treadmill over a 156 
3 km distance (Figure 1). 157 
Each participant was required to perform a 3km time-trial on 158 
three occasions in a randomised, single blind, repeated measures 159 
design with a minimum of 7 days between trials. Participants 160 
were instructed to follow the same 24-hour dietary intake prior 161 
to each trial and were instructed to abstain from caffeine for 6 162 
hours before attending. Prior to completing the 3 km time-trial 163 
participants completed baseline maximal flow-volume 164 
manoeuvre in accordance with ERS/ATS criteria.24 Following 165 
baseline spirometry participants inhaled either eight inhalations 166 
of non-active inhalant (placebo), four inhalations of non-active 167 
inhalant plus four inhalations of 0.5 mg terbutaline (2 mg) or 168 
eight inhalations of 0.5 mg terbutaline (4 mg). Participants 169 
received the inhaled terbutaline via turbuhaler (Bricanyl, 170 
Turbuhaler, AstraZeneca, Canada), participants were advised to 171 
inhale at a steady flow-rate for 2 seconds until full inhalation and 172 
to hold each inhalation for 10 seconds, a minimum of 1 minute 173 
was required between each subsequent inhalation. Ten minutes 174 
post-inhalation spirometry was repeated, before the completion 175 
of a standardised warm-up (5 minutes on a motorized treadmill 176 
at 10 kph). The 3km time-trials were performed under controlled 177 
laboratory conditions of 18°C, 20.9% O2 and 40% humidity. 178 
During the time-trial participants wore a heart rate monitor 179 
(Polar RS400; Polar Electro Oy, Kempele, Finland) and face-180 
mask connected to a breath-by-breath gas analyser (Oxycon Pro, 181 
Jaeger, Wurzberg, Germany). Every 0.5 km the following 182 
variables were measured: time (s), heart rate (HR), oxygen 183 
consumption (?̇?O2), carbon dioxide production (?̇?CO2), minute 184 
ventilation (?̇?E), respiratory exchange ratio (RER) and rating of 185 
perceived exertion (RPE).26 Two minutes following the 186 
completion of the 3 km time-trial a finger-tip capillary blood 187 
sample was collected to measure blood lactate concentration 188 
(Lactate Pro, Arkray KDK, Japan) followed by spirometry and 189 
collection of a post-exercise urine sample (Figure 1).  190 
During the 3 km time-trial participants were only given feedback 191 
on the distance they had covered. They were blind to all other 192 
feedback such as time and HR. Participants were encouraged to 193 
complete the time-trial as fast as possible, a-priori power 194 
calculations for the 3 km running time-trial predicted that for an 195 
expected completion time of 1100 seconds, with a standard 196 
deviation of (14%) 154 seconds, a sample size of 8 would be 197 
sufficient to significantly (P<0.05) predict a 2.5% 27 second 198 
change in performance with 80% power. 199 
Urinalysis 200 
Collected urine-samples were measured for pH and osmolality 201 
before 30 ml of each sample was distributed into a Nalgene 202 
bottle (Thermo Fisher Scientific, Leicestershire, UK) prior to 203 
freezing the sample at -80 ºC until urinalysis. All urinalysis was 204 
performed at HFL Sport Science (Fordham, United Kingdom), 205 
an independent drug surveillance laboratory and former WADA-206 
accredited laboratory. All samples were packaged in dry ice 207 
during transportation to prevent thawing. The laboratory used a 208 
validated proprietary analytical method. In brief, urine samples 209 
were thawed, centrifuged and subaliquotted prior to addition of 210 
a deuterated internal standard (Terbutaline D3; CDN Isotopes via 211 
QMX Laboratories Ltd, Thaxted, UK). Following overnight 212 
enzymatic hydrolysis with β glucuronidase from E. Coli (type 213 
1X-A; Sigma Aldrich, Dorset, UK), sample clean-up was 214 
performed using solid phase extraction (Strata XC 30 mg 96-215 
well plate; Phenomenex, Macclesfield, UK). After elution, 216 
samples were evaporated to dryness, reconstituted and analysed 217 
using an AB Sciex 4000 QTrap mass spectrometer (AB Sciex, 218 
Warrington, UK), with a Waters Acquity UPLC system (Waters 219 
Ltd, Elstree, UK). Chromatographic separation was achieved 220 
using a Waters Acquity HSS T3 Column (2.1 x 100 mm, particle 221 
size 1.8 µm) and gradient solvent programme using methanol 222 
and water, both containing 10 mM ammonium formate.  223 
 224 
Sample concentrations were measured using a calibration line 225 
containing Terbutaline at different concentrations (10 to 3000 226 
ng·ml-1) which were extracted and analysed in the same batch. 227 
Quality control samples were tested along with samples to 228 
confirm assay performance. 229 
 230 
Sample Correction 231 
All urine concentrations of terbutaline were corrected to a urine 232 
specific gravity of 1.02 prior to analysis using the following 233 
equation12: 234 
  235 
Corrected urine concentration = terbutaline urine concentration 236 
x (0.02/(urine specific gravity -1)). 237 
 238 
Statistical Analysis 239 
Statistical analysis incorporated one-way repeated measures 240 
analysis of variance (ANOVA) to compare between trial 241 
conditions during time-trial performance and two-way ANOVA 242 
to compare spirometry measurements between conditions at 243 
different time-points, a Bonferroni correction was applied to 244 
correct for multiple comparisons. Significance was set at P < 245 
0.05 for all analyses. All data were reported as mean (±SD) 246 
unless otherwise stated. Statistical analysis was performed using 247 
the statistical package for the social sciences (SPSS v21.0, IBM, 248 
New York). 249 
 250 
Results 251 
Sixteen participants successfully completed all trials, participant 252 
demographics and lung function screening values are shown in 253 
Table 1. No adverse side-effects were reported by any of the 254 
participants during the study. 255 
 256 
There were no significant differences in completion time 257 
between trials either within the combined group (1103 ± 194 s; 258 
1106 ± 118 s; 1098 ± 160 s; P = 0.9) or when groups were split 259 
according to gender: female (1249 ± 149.3 s; 1257 ± 112 s; 1215 260 
± 96 s; P = 0.37) and male (956 ± 102 s; 955 ± 113 s; 982 ± 122 261 
s; P = 0.28) for PLA, 2 mg and 4 mg trials respectively (Figure 262 
2).  263 
Post time trial blood lactate was greater following 4 mg inhaled 264 
terbutaline (10.7 ± 2.3 mmol·L-1) when compared to the placebo 265 
trial (8.9 ± 1.8 mmol·L-1; P = 0.02; Figure 3). There were no 266 
differences in gas exchange variables for VO2 (49.1 ± 7.7; 49.3 267 
± 5.2; 48.9 ± 5.1) VCO2 (50.3 ± 5.9; 52.5 ± 5.5; 52.1 ±4.5) or 268 
RER (1.08 ± 0.1; 1.09 ± 0.05; 1.12 ± 0.07), for placebo, 2 mg 269 
inhaled and 4 mg inhaled terbutaline, respectively. 270 
Exercising heart rate (HR) did not differ (P=0.95) between trial 271 
conditions, ratings of perceived exertion (RPE) values did not 272 
differ between trials at any time-point during performance 273 
(Figure 4). 274 
There was a significant difference in FEV1 between trial 275 
conditions post-inhalation of 2 mg and 4 mg terbutaline (Table 276 
2). There were no differences between FEV1 values in the 277 
placebo trial following terbutaline administration or following 278 
time-trial completion, there was no difference in baseline lung 279 
function values between conditions. There was a significant 280 
difference in post inhalation FEV1 values compared to placebo 281 
(P=0.007; P=0.003) for both 2 mg and 4 mg inhalation trials, 282 
respectively (Table 2; Figure 5). Interestingly, the difference in 283 
FEV1 post time-trial between conditions was not significant 284 
(P=0.06) (Figure 5), possibly due to a slightly raised FEV1 285 
following exercise in the placebo trial.  286 
There was no significant difference (P=0.195) in urine 287 
concentration between either the 2 mg inhalation or the 4 mg 288 
inhalation post time-trial in males or females with mean ± SD 289 
for the pooled groups (306 ± 288 ng·mL-1; 435 ± 410 ng·mL-1) 290 
and the peak values (956 ng·mL-1; 1244 ng·mL-1) for 2 mg 291 
inhaled terbutaline and 4 mg inhaled terbutaline, respectively 292 
(Figure 6).   293 
 294 
Discussion 295 
This study demonstrates that inhaled terbutaline (up to 4 mg) 296 
does not lead to improved 3 km running time-trial performance 297 
in recreationally active individuals. This is despite an observed 298 
small improvement in FEV1 and an increase in post-exercise 299 
lactate (4 mg terbutaline only) when compared to placebo.  300 
Our study is in agreement with others that suggest there is no 301 
significant effect on endurance performance following a high 302 
dose of inhaled terbutaline.8,9 Previous work investigating the 303 
effects of oral supra-therapeutic doses of terbutaline (8 mg) 304 
failed to show an ergogenic effect on endurance performance 305 
and maximal sprint cycling performance.7 Further experiments 306 
performed by Kalsen et al.,8 examined the effects of high-dose 307 
(15 mg) inhaled terbutaline on 300 kcal cycling time-trial 308 
performance, there was no difference in completion times (1054 309 
± 125 s; 1072 ± 145 s) for placebo vs 15 mg inhaled terbutaline, 310 
respectively. These results are comparable to the present study 311 
in which completion times were (1102 ± 125 s; 1098 ± 109 s) in 312 
the pooled groups for placebo vs 4 mg inhaled terbutaline, 313 
respectively. This evidence supports a lack of ergogenic 314 
potential for terbutaline in moderate duration (~1100 s) 315 
endurance running and cycling performance.  316 
Hostrup et al.,9 reported that high-dose (15 mg) inhaled 317 
terbutaline increased muscle strength, and maximal sprint 318 
cycling performance but did not enhance endurance cycling 319 
performance. In line with these findings, further examination of 320 
this acute dose of 15 mg inhaled terbutaline was performed by 321 
Kalsen et al.,14 investigating the effects on maximal 10s sprint 322 
cycling performance, with the finding that the observed increase 323 
in power output was also associated with increased levels of 324 
plasma lactate. They concluded that for a short period of time, 325 
terbutaline can counteract a reduction in ATP in type II muscle 326 
fibres, further enhancing maximal sprint potential. The general 327 
consensus from Kalsen et al.,14 and Hostrup et al.,9 was that 15 328 
mg inhaled terbutaline promotes a shift towards anaerobic 329 
carbohydrate metabolism during exercise, which may lead to 330 
greater power production in short-term anaerobic activity and 331 
greater fatigability over longer duration aerobic activity.8,9,14,17,18 332 
Following the 4 mg inhaled terbutaline condition we observed 333 
an increase in post-exercise lactate (10.7 ± 2.3 mmol·L-1) when 334 
compared to placebo (8.9 ± 1.8 mmol·L-1). This may be, in part, 335 
due to enhanced Ca2+ release and increased contractile properties 336 
of skeletal muscle following terbutaline administration.14,17,18 337 
Hostrup et al.,18 suggest that this enhanced contractility of 338 
skeletal muscle leads to elevated glycolytic activity during high-339 
intensity exercise. These findings are in accordance with the 340 
findings of Kalsen et al.,8 when investigating the effect of high-341 
dose (15 mg) terbutaline on steady state exercise and also 300 342 
kcal time-trial cycling performance, where lactate accumulation 343 
was higher during steady state exercise and was found to be 344 
attributable to higher rates of glycogenolysis and glycolysis, 345 
with no concomitant improvement in endurance performance. In 346 
association with the findings of Kalsen et al.,8 it is possible that 347 
the lack of ergogenic effect seen in both our study and the study 348 
by Sanchez et al.,7 can be explained by an earlier onset of fatigue 349 
during endurance performance due to enhanced glycolytic 350 
activity induced by terbutaline.9,14  351 
The improvements seen in other studies with regard to sprint and 352 
power performance, could be due to greater potentiation of 353 
adrenergic receptors at very high dosages, according to Baker et 354 
al.,27 a combination of selective affinity and intrinsic efficacy 355 
(ability to induce a response) dictate the strength of response at 356 
a given receptor. A highly selective partial agonist of the β2-357 
receptor such as terbutaline, with high intrinsic efficacy, given 358 
at a supra-therapeutic dose would have the ability to bind to the 359 
β2-receptors in many types of tissue, increasing the ergogenic 360 
potential of the drug.27 This could be one factor that could 361 
support the ergogenic effects found in those studies examining 362 
15 mg inhaled terbutaline for strength and power 363 
performance.9,14,17,18 With this in mind, the distribution of the 364 
high therapeutic dose (4 mg) in the present study, would likely 365 
have been lower than that of the 15 mg inhaled dose studies, 366 
therefore there could have been a lower potency of the β2-agonist. 367 
Given that the present study’s evidence stems from 368 
recreationally active individuals, it is likely that these results are 369 
transferrable to highly trained individuals, (i.e. the physiological 370 
response would be the same in both groups). Although this is a 371 
limitation, ethically, it would not have been possible to perform 372 
this study in an elite population, due to the athletes’ 373 
responsibility to undertake out-of-competition testing.  374 
A TUE is needed for the use of inhaled terbutaline during 375 
competition, largely due to the inability to distinguish between 376 
route of administration and total dose administered.12,16,28 In the 377 
present study we were able to measure urine concentrations of 2 378 
mg and 4 mg doses of terbutaline, interestingly our values for 2 379 
mg (305.5±288.3 ngˑml-1) inhaled terbutaline are lower than 380 
those found in a previous investigation by Elers et al.,12 for 2 mg 381 
inhaled terbutaline (472±324 ngˑml-1) and our values after 4 mg 382 
inhaled terbutaline (435.4±409.8 ng·mL-1) are comparable to the 383 
values after 10 mg oral terbutaline in the Elers et al.,12 study 384 
(402±663 ngˑml-1). Interestingly, these values for both varying 385 
dosages and alternate routes of administration have very similar 386 
mean values, further highlighting the difficulty in distinguishing 387 
between therapeutic and supra-therapeutic use of terbutaline.12 388 
Of note, the timing of the urine sample in the Elers et al.,12 study 389 
was at 4 hours, whereas in the present study urine samples were 390 
collected 1-hour post-inhalation. Indeed, serum concentrations 391 
of terbutaline reached a peak at the 4-hour stage in the Elers et 392 
al.,12 study, therefore it is possible that inhaled terbutaline may 393 
not have reached peak levels in the urine at the 1-hour sample 394 
collection in the present study. The 4 mg inhaled dose was 395 
previously examined by Dyreborg et al.,16 with peak 396 
concentrations reaching 1954 ng·mL-1 at the 2 hour stage post-397 
inhalation, the present study found peak concentrations reaching 398 
1244 ng·mL-1 1 hour post-inhalation, it would have been 399 
beneficial to examine urinary levels of terbutaline at additional 400 
timepoints in the present study in order to ascertain time to 401 
maximal concentration (Tmax) of terbutaline. A number of factors 402 
contribute to the varying levels of urinary terbutaline, recent 403 
work by Kreiberg et al.,29 indicate varying pharmacokinetics of 404 
4 mg inhaled terbutaline dependent upon external factors such as 405 
exercise performance and also environmental conditions, these 406 
differences exist post-correction for urine specific gravity, 407 
explanations for such variance include but are not limited to; 408 
inhalation technique, exercise intensity and hydration status. 409 
In the investigations by Elers et al.,12 and Dyreborg et al.,16 410 
significant differences were found between oral and inhaled 411 
doses, but no cut-off value could be established. If a cut-off value 412 
were able to be established then it is possible that inhaled 413 
terbutaline would be able to be monitored in much the same way 414 
as both salbutamol and formoterol, where an AAF would 415 
indicate possible supra-therapeutic inhaled use or oral 416 
administration, which have established ergogenic potential in 417 
strength and power performance.7–9,14,17,18 Further investigation 418 
is needed to establish the ergogenic effects of therapeutic inhaled 419 
terbutaline on sprint and power performance. Recent findings 420 
also highlight that daily use of 4 mg inhaled terbutaline displays 421 
repartitioning properties, allowing for reductions in body fat and 422 
increases in muscle mass.30 Care is warranted with regard to the 423 
use of terbutaline in athletes with a TUE. 424 
Practical Applications 425 
Therapeutic use of terbutaline in athletes with a TUE will not 426 
lead to an ergogenic advantage during running-based endurance 427 
exercise. Investigations into appropriate monitoring of 428 
terbutaline are warranted in order to prevent the potential misuse 429 
of terbutaline via supratherapeutic dosing. 430 
Conclusions 431 
The findings of the present study suggest that therapeutic doses 432 
of inhaled terbutaline (up to 4 mg) do not improve 3 km running 433 
time-trial performance. Endurance running athletes using 434 
inhaled terbutaline via TUE, as therapy for their asthma, are 435 
therefore unlikely to experience an additional ergogenic 436 
advantage. Further research is needed investigating the effects of 437 
therapeutic inhaled doses of terbutaline during strength and 438 
power performance to fully elucidate any ergogenic potential. 439 
 440 
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  580 
Tables 581 
 582 
Table 1: Mean (±SD) Participant Demographics and Lung Function at Baseline and % Change in Lung Function Post-EVH in Males and Females. 
Group 
Height 
(cm) 
Weight 
(kg) 
Age  
(yrs) 
Baseline 
FEV1 (L) 
% 
Predicted 
FEV1 
Baseline 
FVC (L) 
% 
Predicted 
FVC 
FEV1/FVC 
Ratio 
Baseline   
PEF (L) 
% 
Predicted 
PEF 
Post-EVH 
% Fall in 
FEV1 
Males 
(n=8) 
179.5 (4.3) 77.6 (8) 24.3 (2.4) 5.2 (0.2) 114 (4.6) 5.9 (0.6) 110.5 (8.2) 0.83 (0.05) 580.6 (57.9) 96 (10) 5.1 (6.1) 
Females 
(n=8) 
163 (9.2) 58.6 (6) 22.4 (3) 3.6 (0.5) 108.9 (13.4) 3.93 (0.5) 105.3 (12) 0.92 (0.03) 439.1 (75.7) 102.8 (17.8) 3.8 (1.6) 
FEV1 - Forced Expiratory Volume in 1 Second; EVH - Eucapnic Voluntary Hyperpnoea; FVC – Forced Vital Capacity; PEF – Peak Expiratory Flow 
ECCS – European Community for Coal and Steel Reference Values for Predicted Lung Function 
 583 
 584 
Table 2: FEV1 (L) for trial conditions at baseline, post inhaler and post time trial in the pooled group 
 Time point Placebo 2 mg 4 mg 
Baseline 4.81 ± 0.55  4.84 ± 0.54  4.80 ± 0.55  
Post Inhaler 4.83 ± 0.54  5.08 ± 0.55*     5.07 ± 0.48†  
Post Time-Trial 4.87 ± 0.56  5.07 ± 0.55  5.04 ± 0.49  
Significantly different from placebo       * P=0.01      † P=0.02 
FEV1 – Forced Expiratory Volume in 1 Second 
 585 
 586 
Figure 1: a) Study duration, progression and randomisation protocol b) Schematic diagram of the test procedures during the 60-minute trial visit 587 
 588 
 589 
Figure 2: Mean and individual 3km running time-trial completion times for a) females and b) males following placebo, 2 mg inhaled terbutaline and 4 590 
mg inhaled terbutaline trial conditions. 591 
 592 
 593 
 594 
Figure 3: Mean (±SD) Lactate values post 3km running time-trial for placebo, 2 mg inhaled terbutaline and 4 mg inhaled terbutaline conditions.  595 
 596 
 597 
 598 
Figure 4: Exercising values (Mean ± SD) for: Heart Rate (HR) in a) females b) males and rating of perceived exertion (RPE) in c) females d) males during 599 
each of the three trial conditions, placebo, 2 mg inhaled terbutaline and 4 mg inhaled terbutaline. 600 
 601 
 602 
 603 
Figure 5: Mean (± SD) change in FEV1 from baseline post-inhalation and post-time-trial completion for placebo, 2 mg inhaled terbutaline and 4 mg 604 
inhaled terbutaline.  605 
ΔFEV1 – Change in FEV1 compared to baseline 606 
 607 
 608 
 609 
 610 
Figure 6: Individual peak and mean (± SD) urinary concentrations 1 hour post terbutaline inhalation in the 2 mg inhaled and 4 mg inhaled terbutaline 611 
trials in males and females. 612 
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